The first-ever reverse-aging drug was just injected into a humanNEWS | 09 June 2026A first-of-its-kind shot that promises to reverse aging was just injected into a human body.
It's a pivotal moment for longevity science, the first opportunity for researchers to prove that epigenetic reprogramming — a technique that trains aging cells to act young again — can actually improve how people age in the real world.
On Tuesday, Boston-based biotech startup Life Biosciences announced that its first patient has been dosed with a cellular reprogramming injection, designed to reverse age-related diseases.
Billionaires, including Jeff Bezos and Sam Altman, as well as pharmaceutical giants Eli Lilly and Merck, have been increasingly investing in this idea, which, until now, had been relegated to mouse and monkey research.
If this first human trial is successful, it could usher in a new era of aging therapies aimed at making cells more youthful across the body, in a bid to improve how our DNA is expressed as we age.
In this case, the injection went into one eyeball of a single person with glaucoma. The company did not share any other information about the patient. Over the next six months, scientists will be watching to see how well the technique works, while doctors keep an eye out for any safety issues.
"To me, it represents a potential transformational moment, not only for the company, not only for the field of aging biology, but I think potentially, and I don't say this lightly, for medicine," Life Biosciences CEO Jerry McLaughlin told Business Insider, shortly before the news was announced.
"We're really looking at the ability to restore function, to reverse disease at a very fundamental level in the body."
What is cellular reprogramming? Unpacking the hottest trend in longevity science
Sam Altman is investing in cellular reprogramming, which aims to reset cells, making old cells act brand new again. Xavier Collin/Image Press Agency/NurPhoto/Reuters
The concept of cellular reprogramming has been one of the most tantalizing theories in longevity science for almost two decades.
In 2007, scientist and surgeon Shinya Yamanaka first successfully reprogrammed adult human cells, work that later won him a Nobel Prize. The "Yamanaka Factors," as they are now called, are four specific proteins that he discovered can reprogram cells, basically making old cells act brand new again.
Longevity scientists would like to unlock new ways to partially reprogram old cells, so they don't get completely reprogrammed into newborn ("undifferentiated") stem cells, but instead can act more youthful and resilient, while still maintaining their identity and role in the body. Two hot areas of research include liver cells and muscle cells. The goal is to improve how the cells in these tissues perform, optimizing our strength and vitality as we get older.
In recent years, multiple researchers and companies have been throwing wads of cash at this idea, trying to unlock the best way to safely and effectively test partial reprogramming in a living person without pushing cells all the way back to their birth state.
Pharmaceutical giants are beginning to take notice. This month, Eli Lilly was part of a late-stage $435 million series C funding round for New Limit, another biotech startup focused on cellular reprogramming. Merck Animal Health just poured new funding into Rejuvenate Bio. And tech titans Jeff Bezos and Sam Altman are also funding Silicon Valley startups, Altos Labs and Retro Biosciences based on this buzzy concept.
But Life Biosciences is the first to test this in humans, with a little under 20 patients slated to participate in the initial FDA trial of ER-100. Clinics in Boston, New York City, Los Angeles, and Charleston are recruiting patients with either glaucoma or NAION (non-arteritic anterior ischemic optic neuropathy), a common cause of sudden vision loss.
The company's cofounder, Harvard geneticist David Sinclair , is one of the most well-known and controversial figures in longevity science. Sinclair, who's no longer involved in the day-to-day operations at Life Biosciences, has been known for hyping up his own experimental anti-aging treatments that have never quite met expectations. But for all his misses, his ideas helped lay the foundation for this new trial, which, if successful, could be groundbreaking.
The risks and rewards of achieving cellular reprogramming are both sky-high
Cellular reprogramming has been linked to cancer in animal trials. yacobchuk/Getty Images
The potential for cellular reprogramming to reshape how doctors diagnose and treat disease is massive.
If cells can be re-engineered to perform better as we age, there are applications well beyond better eyesight and stronger muscles. The therapies could, one day, extend healthy life. (Though any potential drug in this category is still likely more than a decade away from being FDA-approved.)
"I think we're in the early days of showing the technology works, and it absolutely makes sense to start in the eye, but I think it gets truly exciting when we start getting towards these ideas of systemic changes," Daniel Oliver, the CEO and co-founder of cellular reprogramming startup Rejuvenate Bio, told Business Insider.
"These technologies get really, really exciting when you go into things like muscle, possibly liver, neuronal tissue, where we absolutely know that when you have positive effects there, it tends to have positive effects across the body."
A big concern with cellular reprogramming is cancer. Critics have been worried because two of the four cellular reprogramming factors Yamanaka identified are oncogenes, which can divide indefinitely. In cellular reprogramming research on mice, some have developed cancerous tumors.
In the case of Life Biosciences, researchers are controlling their reprogramming therapy with a pill-based on/off switch — participants in this trial are taking the common antibiotic doxycycline daily to activate the therapy. If there are safety concerns during the trial, patients could stop taking their daily pill, and the cellular reprogramming will stop. They're also only using three of the four Yamanaka factors in this therapy, skipping the one that is most closely associated with cancer development.
Longevity scientists acknowledge that these therapies have the potential to make a significant difference in how we age, with a much greater impact than supplements or repurposed generic drugs.
They're also cautious. On a recent episode of longevity researcher Matt Kaeberlein's podcast, he asked his colleague Brian Kennedy, who directs the Centre for Healthy Longevity at the National University Health System in Singapore, what he thought about where this is all headed.
"I am supportive of the concept of epigenetic reprogramming, partly because I think that it has, conceptually, the potential to have a big effect on aging if it can be done correctly," Kennedy said on the podcast. "I've always been skeptical that we have enough knowledge to do that safely and effectively in a human."
"Having said that, this is an interesting place to look," he added, since the eye is semi-protected and sheltered from the rest of the body, it's "presumably going to have less side effects."Author: More Stories. Hilary Brueck. Every Time. Look Out For An Alert In Your Inbox The Next Time. Source
